不合理抗菌药物联合使用的增加：是否需要临床判例？
The Rise of Irrational Antimicrobial Combinations: Need for Clinical Jurisprudence?
作者信息
Kundu Riddhi, Baronia Tanima, Sathe Prachee
机构信息
Department of Critical Care Medicine, Ruby Hall Clinic, Pune, Maharashtra, India.
出版信息
Indian J Crit Care Med. 2024 Jun;28(6):618-619. doi: 10.5005/jp-journals-10071-24718.
Abstract
Kundu R, Baronia T, Sathe P. The Rise of Irrational Antimicrobial Combinations: Need for Clinical Jurisprudence? Indian J Crit Care Med 2024;28(6):618-619.
摘要
昆杜 R、巴罗尼亚 T、萨特 P。不合理抗菌药物联合使用的增加：临床判例法的必要性？《印度危重症医学杂志》2024 年；28(6)：618 - 619。
相似文献
1
The Rise of Irrational Antimicrobial Combinations: Need for Clinical Jurisprudence?不合理抗菌药物联合使用的增加：是否需要临床判例？
Indian J Crit Care Med. 2024 Jun;28(6):618-619. doi: 10.5005/jp-journals-10071-24718.
2
Multidrug Resistance: The Growing Menace in PICU.多重耐药性：儿科重症监护病房中日益严重的威胁
Indian J Crit Care Med. 2023 Jan;27(1):6-7. doi: 10.5005/jp-journals-10071-24394.
3
Management of CRE Infections: High Time for an RCT?耐碳青霉烯类肠杆菌科细菌感染的管理：是时候进行一项随机对照试验了吗？
Indian J Crit Care Med. 2024 May;28(5):516-517. doi: 10.5005/jp-journals-10071-24646.
4
Empathy: An Essential Skill in the Intensive Care Units.同理心：重症监护病房中的一项基本技能。
Indian J Crit Care Med. 2019 Sep;23(9):391. doi: 10.5005/jp-journals-10071-23230.
5
Antimicrobial Stewardship Program in Critical Care-Need of the Hour.重症监护中的抗菌药物管理计划——刻不容缓的需求。
Indian J Crit Care Med. 2020 Sep;24(9):847-854. doi: 10.5005/jp-journals-10071-23557.
6
Approach to the Control of Antimicrobial Resistance: Are We Missing the Plot?抗菌药物耐药性控制方法：我们是否忽略了关键所在？
Indian J Crit Care Med. 2020 Oct;24(10):899-900. doi: 10.5005/jp-journals-10071-23626.
7
Necrotizing Soft Tissue Infections: More than What Meets the Eye.坏死性软组织感染：表象之外的更多情况
Indian J Crit Care Med. 2022 Summer;26(4):411-413. doi: 10.5005/jp-journals-10071-24196.
8
Trendelenburg in Acute Respiratory Distress Syndrome: Should We Do More than Proning?急性呼吸窘迫综合征中的头低脚高位：除了俯卧位通气，我们还应做更多吗？
Indian J Crit Care Med. 2022 Aug;26(8):976-977. doi: 10.5005/jp-journals-10071-24275.
9
Parturient with Acute Abdomen.伴有急腹症的产妇
Indian J Crit Care Med. 2021 Dec;25(Suppl 3):S223-S229. doi: 10.5005/jp-journals-10071-24013.
10
Study of Antimicrobial Utilization and Cost of Therapy in Medicine Intensive Care Unit of a Tertiary Care Hospital in Eastern India.印度东部一家三级护理医院内科重症监护病房抗菌药物使用及治疗费用研究
Indian J Crit Care Med. 2020 Oct;24(10):938-942. doi: 10.5005/jp-journals-10071-23552.
本文引用的文献
1
Takeaways from the Recarbrio Conundrum: Has the FDA Jumped the Gun?《瑞卡必利难题的启示：美国食品药品监督管理局是否操之过急？》
Indian J Microbiol. 2023 Dec;63(4):702-703. doi: 10.1007/s12088-023-01105-5. Epub 2023 Oct 3.
2
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.美国传染病学会2023年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
3
Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis.头孢他啶-阿维巴坦联合或不联合氨曲南与基于多黏菌素的联合疗法治疗耐碳青霉烯类肠杆菌科细菌：一项回顾性分析
Indian J Crit Care Med. 2023 Jun;27(6):444-450. doi: 10.5005/jp-journals-10071-24481.
4
New antimicrobial treatment options for severe Gram-negative infections.严重革兰氏阴性感染的新抗菌治疗选择。
Curr Opin Crit Care. 2022 Oct 1;28(5):522-533. doi: 10.1097/MCC.0000000000000968. Epub 2022 Aug 4.
5
A Comparative Sensitivity Study of "Ceftriaxone-Sulbactam-EDTA" and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit.“头孢曲松-舒巴坦-乙二胺四乙酸”与多种抗生素对重症监护病房革兰氏阴性菌分离株的敏感性比较研究
Indian J Crit Care Med. 2020 Dec;24(12):1213-1217. doi: 10.5005/jp-journals-10071-23573.
6
CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial.头孢曲松+舒巴坦+乙二胺四乙酸二钠（CSE）与美罗培南治疗复杂性尿路感染（包括急性肾盂肾炎）的疗效比较：PLEA，一项双盲、随机、非劣效性试验
Open Forum Infect Dis. 2019 Oct 1;6(10). doi: 10.1093/ofid/ofz373.
7
Mechanisms of Polymyxin Resistance.多粘菌素耐药机制。
Adv Exp Med Biol. 2019;1145:55-71. doi: 10.1007/978-3-030-16373-0_5.
8
β-Lactams and β-Lactamase Inhibitors: An Overview.β-内酰胺类与β-内酰胺酶抑制剂：概述
Cold Spring Harb Perspect Med. 2016 Aug 1;6(8):a025247. doi: 10.1101/cshperspect.a025247.
Zotero 插件